Inflammation in schizophrenia: pathogenetic aspects and therapeutic considerations.
Open accessThe DOI matches its Crossref record; 128 of the 130 references it cites were found in a registry or an index.
Abstract
This paper discusses the current evidence from animal and human studies for a central role of inflammation in schizophrenia. In animal models, pre- or perinatal elicitation of the immune response may increase immune reactivity throughout life, and similar findings have been described in humans. Levels of pro-inflammatory markers, such as cytokines, have been found to be increased in the blood and cerebrospinal fluid of patients with schizophrenia. Numerous epidemiological and clinical studies have provided evidence that various infectious agents are risk factors for schizophrenia and other psychoses. For example, a large-scale epidemiological study performed in Denmark clearly showed that severe infections and autoimmune disorders are such risk factors. The vulnerability-stress-inflammation model may help to explain the role of inflammation in schizophrenia because stress can increase pro-inflammatory cytokines and may even contribute to a chronic pro-inflammatory state. Schizophrenia is characterized by risk genes that promote inflammation and by environmental stress factors and alterations of the immune system. Typical alterations of dopaminergic, serotonergic, noradrenergic, and glutamatergic neurotransmission described in schizophrenia have also been found in low-level neuroinflammation and consequently may be key factors in the generation of schizophrenia symptoms. Further support for the relevance of a low-level neuroinflammatory process in schizophrenia is provided by the loss of central nervous system volume and microglial activation demonstrated in neuroimaging studies. Last but not least, the benefit of anti-inflammatory medications found in some studies and the intrinsic anti-inflammatory and immunomodulatory effects of antipsychotics provide further support for the role of inflammation in this debilitating disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Evidence of altered inflammation-related markers across psychiatric conditions [6–8], along with reports of anti-inflammatory effects from psychotropic medications [9, 10] and the ameliorative impact of anti-inflammatory drugs on psychiatric symptoms [11–14], suggests a strong link between abnormal inflammatory responses and major psychiatric disorders.”
From Inflammatory ratios as predictors of length of hospitalization in psychiatric patients: A multicenter study (2025) · doi:10.1007/s00406-025-02033-9 · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A growing body of evidence suggests that immune dysfunction and inflammation have been considered to play important roles in the pathogenesis of SCZ and BD (11, 12).”
From Investigation of systemic immune-inflammation index, neutrophil/high-density lipoprotein ratio, lymphocyte/high-density lipoprotein ratio, and monocyte/high-density lipoprotein ratio as indicators of inflammation in patients with schizophrenia and bipolar disorder (2022) · cites this paper as [12]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Changes of some inflammation-related factors (IRFs) have been intensively studied and reviewed in relation to psychiatric disorders1–9.”
From Inflammation-related biomarkers in major psychiatric disorders: a cross-disorder assessment of reproducibility and specificity in 43 meta-analyses (2019) · cites this paper as [6]
The cited source says what the claim attributes to it.
In the citing paper
“Recent evidence suggests the involvement of the immune system in several psychiatric conditions [203–205]; one of the most studied in this respect is depression [206–208].”
From Molecular Characterisation of the Mechanism of Action of Stimulant Drugs Lisdexamfetamine and Methylphenidate on ADHD Neurobiology: A Review (2022) · cites this paper as [203]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Murphy, K., & Weaver, C. (2016) · W.W. Norton eBooks · doi:10.1201/9781315533247 · Cited by 2,258
Vulnerability: A new view of schizophrenia.
Zubin, J., & Spring, B. (1977) · Journal of Abnormal Psychology · doi:10.1037/0021-843x.86.2.103 · Cited by 1,992
Cortical demyelination and diffuse white matter injury in multiple sclerosis
Kutzelnigg, A., Lucchinetti, C. F., Stadelmann, C., Brück, W., Rauschka, H., Bergmann, M., Schmidbauer, M., Parisi, J. E., & Lassmann, H. (2005) · Brain · doi:10.1093/brain/awh641 · Cited by 1,836
Goldsmith, D. R., Rapaport, M. H., & Miller, B. J. (2016) · Molecular Psychiatry · doi:10.1038/mp.2016.3 · Cited by 1,683
Raison, C. L., Rutherford, R. E., Woolwine, B. J., Shuo, C., Schettler, P., Drake, D. F., Haroon, E., & Miller, A. H. (2013) · JAMA Psychiatry · doi:10.1001/2013.jamapsychiatry.4 · Cited by 1,617
Maternal Immune Activation Alters Fetal Brain Development through Interleukin-6
Smith, S. E. P., Li, J., Garbett, K., Mirnics, K., & Patterson, P. H. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.2178-07.2007 · Cited by 1,605
Serologic Evidence of Prenatal Influenza in the Etiology of Schizophrenia
Brown, A. S., Begg, M. D., Gravenstein, S., Schaefer, C. A., Wyatt, R. J., Bresnahan, M., Babulas, V. P., & Susser, E. S. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.8.774 · Cited by 1,053
The current status of the dopamine hypothesis of schizophrenia
CARLSSON, A. (1988) · Neuropsychopharmacology · doi:10.1016/0893-133x(88)90012-7 · Cited by 958
Neuropharmacology of quinolinic and kynurenic acids.
Stone, T. W. (1993) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)00441-7 · Cited by 948
Cytokine-induced sickness behavior: where do we stand?
Dantzer, R. (2001) · Brain, Behavior, and Immunity · doi:10.1006/brbi.2000.0613 · Cited by 862
Cited by
Items 101–200 of 648
Toriumi, K., Berto, S., Koike, S., Usui, N., Dan, T., Suzuki, K., Miyashita, M., Horiuchi, Y., Yoshikawa, A., Asakura, M., et al. (2021) · Redox Biology · doi:10.1016/j.redox.2021.102057 · Cited by 38
“Clinical studies have reported that the aberrant inflammation is frequently seen in schizophrenia and related psychoses [82,83].”
Background(Micro)Glia as Effectors of Cortical Volume Loss in Schizophrenia
Mallya, A. P., & Deutch, A. Y. (2018) · Schizophrenia Bulletin · doi:10.1093/schbul/sby088 · Cited by 34
Manta, A., Georganta, A., Roumpou, A., Zoumpourlis, V., Spandidos, D. A., Rizos, E. N., & Peppa, Μ. (2025) · Molecular Medicine Reports · doi:10.3892/mmr.2025.13479 · Cited by 49
“These metabolic abnormalities that patients with SCZ exhibit affect the gut microbiota (38), leading to an increase in pro‑ inflammatory bacteria and a decrease in anti‑inflammatory organisms.”
Pharmacological strategies for the management of comorbid depression and schizophrenia
Češková, E. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1717466 · Cited by 33
“the remission of symptoms with antipsychotic treatment [20].”
BackgroundBoiko, A. S., Mednova, I. A., Kornetova, E. G., Gerasimova, V. I., Корнетов, А. Н., LOONEN, A. J. M., Bokhan, N. A., & Ivanova, S. А. (2021) · Pharmaceuticals · doi:10.3390/ph14050446 · Cited by 30
“These modulators affect neighboring astrocytes and neurons, making a significant contribution to the homeostatic regulation of brain tissue [3,4].”
BackgroundPignon, B., Borel, C., Lajnef, M., Richard, J., Szöke, A., Hémery, F., Leboyer, M., Forêt, G., & Schürhoff, F. (2022) · Environmental Science and Pollution Research · doi:10.1007/s11356-022-21964-7 · Cited by 35
“2018) that are considered to be causal mechanisms of psychiatric disorders (Leboyer et al. 2012, 2016; Howes and McCutcheon 2017; Müller 2018).”
Peripheral Biomarkers in Schizophrenia: A Meta-Analysis of Microarray Gene Expression Datasets
Piras, I. S., Manchia, M., Huentelman, M. J., Pinna, F., Zai, C. C. H., Kennedy, J. L., & Carpiniello, B. (2018) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyy103 · Cited by 32
“First, the presence of a downregulation of ALOX15B gene expression in peripheral tissue seems consistent with the neuroinflammatory hypothesis of SCZ (Müller, 2018).”
Hill, S. L., Shao, L., & Beasley, C. L. (2020) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2020.1755451 · Cited by 30
de Souza, D. V., Pappis, L., BANDEIRA, T. L. T., Sangoi, G. G., Fontana, T., Rissi, V. B., Sagrillo, M. R., Duarte, M. M. M. F., Duarte, T., Bodenstein, D. F., et al. (2020) · Nutritional Neuroscience · doi:10.1080/1028415x.2020.1842044 · Cited by 46
“is already known that this fruit has several biological effects, including anti-oxidant, [18,19] antitumor [20], neuroprotective [14,21,22], anti-obesity [23], and even anti-inflammatory effects [19,24,25].”
BackgroundTian, Y., Wang, D., Wei, G., Wang, J., Zhou, H., Xu, H., Dai, Q., Xiu, M., Chen, D., Wang, L., et al. (2020) · Psychopharmacology · doi:10.1007/s00213-020-05727-1 · Cited by 36
“Meanwhile, low-grade inflammation is associated with psychopathological symptoms of schizophrenia (Müller 2018).”
BackgroundAkkouh, I. A., Hříbková, H., Grabiec, M., Budínská, E., Szabó, A., Kašpárek, T., Andreassen, O. A., Sun, Y.-M., & Djurovic, S. (2021) · Schizophrenia Bulletin · doi:10.1093/schbul/sbab092 · Cited by 32
Cheng, Y., Wang, T., Zhang, T., Shu, Y., Zhao, S., Li, N., Yang, Y., Zhang, F., Xu, L., Shan, B., et al. (2022) · Biological Psychiatry Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2022.06.006 · Cited by 40
Neurobiology of Schizophrenia (to the Construction of Clinical and Biological Model)
Klyushnik, T. P., Ab, S., Zozulya, S. A., & Voronova, E. I. (2021) · Psikhiatriya · doi:10.30629/2618-6667-2021-19-1-6-15 · Cited by 30
Goldsmith, D. R., Massa, N., Pearce, B. D., Wommack, E. C., Alrohaibani, A., Goel, N., Cuthbert, B. N., Fargotstein, M., Felger, J. C., Haroon, E., et al. (2020) · Schizophrenia · doi:10.1038/s41537-020-0098-4 · Cited by 31
Complex Gastrointestinal and Endocrine Sources of Inflammation in Schizophrenia
Severance, E. G., Dickerson, F., & Yolken, R. H. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00549 · Cited by 31
Ullah, I., Awan, H. A., Aamir, A., Diwan, M. N., de Filippis, R., Awan, S., Irfan, M., Fornaro, M., Ventriglio, A., Vellante, F., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222313032 · Cited by 35
“Another drug, celecoxib (a COX-2 inhibitor), has also been investigated and trials reported a significantly improved outcome and better functioning cognitive status in groups that were treated with celecoxib and risperidone (antipsychotic) compared to placebo groups [72].”
BackgroundHatzimanolis, A., Foteli, S., Stefanatou, P., Ntigrintaki, A.-A., Ralli, I., Kollias, K., Nikolaou, C. C., Gazouli, M., & Stefanis, N. C. (2022) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-022-01409-5 · Cited by 29
Chukaew, P., Bunmak, N., Auampradit, N., Siripaiboonkij, A., Saengsawang, W., & Ratta‐apha, W. (2022) · Neuropsychopharmacology Reports · doi:10.1002/npr2.12261 · Cited by 27
Baek, S.-H., Kim, H., Kim, J., Ryu, S., Lee, J., Kim, J., Shin, I., & Kim, S. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12071137 · Cited by 34
“In particular, proinflammatory cytokine levels increase in the blood [37] and may affect cognitive functioning in patients with schizophrenia [4].”
BackgroundZhang, T., Zeng, J., Wei, Y., Ye, J., Tang, X., Xu, L., Hu, Y., Cui, H., Xie, Y., Tang, Y., et al. (2022) · Psychiatry Research · doi:10.1016/j.psychres.2022.114938 · Cited by 31
COVID-19 and New-Onset Psychosis: A Comprehensive Review
Moccia, L., Kotzalidis, G. D., Bartolucci, G., Ruggiero, S., Monti, L., Biscosi, M., Terenzi, B., Ferrara, O. M., Mazza, M., Nicola, M. D., et al. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13010104 · Cited by 27
Zhu, Y., Webster, M. J., Walker, A. K., Massa, P. T., Middleton, F. A., & Weickert, C. S. (2023) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2023.03.018 · Cited by 30
In Vitro and In Vivo Models for the Investigation of Potential Drugs Against Schizophrenia
Koszła, O., Targowska‐Duda, K. M., Kędzierska, E., & Kaczor, A. A. (2020) · Biomolecules · doi:10.3390/biom10010160 · Cited by 28
“There are also reports about the role of inflammation [45,46] and oxidative stress [47] in this disease.”
BackgroundRißmayer, M., Kambeitz, J. P., Javelle, F., & Lichtenstein, T. (2024) · Schizophrenia Bulletin · doi:10.1093/schbul/sbae015 · Cited by 28
THE CORRELATION BETWEEN PSYCHIATRIC DISORDERS AND COVID-19: A NARRATIVE REVIEW
He, Y., Yu, R., & Ren, J. (2021) · Psychiatria Danubina · doi:10.24869/psyd.2021.76 · Cited by 28
“It is reported that inflammation plays a role in the pathogenesis of schizophrenia (Müller 2018), depression (Beurel et al. 2020), and bipolar disorder (Benedetti et al. 2020), as well as in the systemic manifestations of SARS-CoV-2 infection (Steardo et al. 2020).”
BackgroundSagheddu, C., Melis, M., Muntoni, A. L., & Pistis, M. (2021) · Pharmaceuticals · doi:10.3390/ph14101025 · Cited by 24
Taşçı, B., Taşçı, G., Ayyıldız, H., Kamath, A. P., Barua, P. D., Tuncer, T., Doğan, Ş., Ciaccio, E. J., Chakraborty, S., & Acharya, U. R. (2023) · Multimedia Tools and Applications · doi:10.1007/s11042-023-16676-0 · Cited by 26
“[5].”
Guo, Y., Singh, L. N., Zhu, Y., Gur, R. E., Resnick, A. C., Anderson, S. A., & Alvarez, J. I. (2019) · Schizophrenia Research · doi:10.1016/j.schres.2019.09.014 · Cited by 26
“neuropathology in SZ have long been implicated (Muller, 2018).”
BackgroundMultiscale Weighted Permutation Entropy Analysis of Schizophrenia Magnetoencephalograms
Bai, D., Yao, W., Wang, S., & Wang, J. (2022) · Entropy · doi:10.3390/e24030314 · Cited by 25
“Individual cases of schizophrenia that exhibit the same symptoms may have different objective genetic backgrounds and brain network characteristics; the underlying etiology and pathogenesis of schizophrenia are still unclear [4,6].”
BackgroundTargeted metabolomics reveals aberrant profiles of serum bile acids in patients with schizophrenia
Qing, Y., Wang, P., Cui, G., Zhang, J., Liang, K., Xia, Z., Wang, P., He, L., & Jia, W. P. (2022) · Schizophrenia · doi:10.1038/s41537-022-00273-5 · Cited by 27
Valiente-Pallejà, A., Torrell-Galceran, H., Alonso, Y., Vilella, E., Muntané, G., & Martorell, L. (2020) · Schizophrenia Research · doi:10.1016/j.schres.2020.03.070 · Cited by 29
“…brain functioning in SZ (Konradi and Öngür, 2017; Pei and Wallace, 2018), in addition to other mitochondria-associated systemic abnormalities, such as inflammation, redox dysregulation and oxidative stress (Fournier et al., 2014; Kim et al., 2017; Kirkpatrick and Miller, 2013; Müller, 2018).”
Li, X., Li, N., Han, Y., Rao, K., Ji, X., & Ma, M. (2021) · Environmental Pollution · doi:10.1016/j.envpol.2021.117302 · Cited by 25
Does COVID-19 infection have an impact on children’s psychological problems?
Ahmed, G. K., Elbeh, K., Gomaa, H. M., & Soliman, S. (2021) · Middle East Current Psychiatry · doi:10.1186/s43045-021-00155-z · Cited by 30
Ershova, E. S., Шмарина, Г. В., Porokhovnik, L. N., Zakharova, N. V., Kostyuk, G. P., Umriukhin, P. E., Kutsev, S. I., Sergeeva, V. A., Veiko, N. N., & Kostyuk, S. V. (2022) · Genes · doi:10.3390/genes13030551 · Cited by 25
Vasile, C. I., Vasile, M.-C., Zlati, M. L., Herbei, E. E., Lepădatu, L., Munteanu, C., Nechifor, A., & Tatu, A. L. (2022) · Infection and Drug Resistance · doi:10.2147/idr.s373578 · Cited by 24
“Even the neurological manifestation of COVID-19 generated speculation regarding the neuropsychiatric sequelae, its inflammatory effect is more relevant to later development of schizophrenia.(51) The Covid-19 provides a unique opportunity regarding the research of the pathogenesis of psychotic disorders.”
BackgroundSchizophrenia and obesity: May the gut microbiota serve as a link for the pathogenesis?
Wu, H., Liu, Y., Wang, J., Chen, S., Xie, L., & Wu, X. (2023) · iMeta · doi:10.1002/imt2.99 · Cited by 26
“The pathophysiology of SZ has also been linked to similar processes [14].”
BackgroundBen‐Azu, B., Adebayo, O. G., Fokoua, A. R., Onuelu, J. E., Asiwe, J. N., Moke, E. G., Omogbiya, I. A., Okpara, O. L., Okoro, J. E., Oghenevwerutevwe, O. M., et al. (2024) · Brain Disorders · doi:10.1016/j.dscb.2024.100122 · Cited by 24
Hajj, A., Obeïd, S., Sahyoun, S., Haddad, C., Azar, J., Khabbaz, L. R., & Hallit, S. R. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20194753 · Cited by 25
Huang, H., Luo, Z., Min, J., Luo, W., Zhou, X., & Wang, C. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.114910 · Cited by 26
Neuroinflammation in Schizophrenia: An Overview of Evidence and Implications for Pathophysiology
Ermakov, E. A., Mednova, I. A., Boiko, A. S., & Ivanova, S. А. (2025) · Journal of Integrative Neuroscience · doi:10.31083/jin27636 · Cited by 31
Świerczek, A., Jankowska, A., Chłoń‐Rzepa, G., Pawłowski, M., & Wyska, E. (2019) · Current Drug Targets · doi:10.2174/1389450120666190801114210 · Cited by 23
Kiltschewskij, D. J., Reay, W. R., Geaghan, M. P., Atkins, J., Xavier, A., Zhang, X., Watkeys, O. J., Carr, V. J., Scott, R. J., Green, M. J., et al. (2023) · Biological Psychiatry · doi:10.1016/j.biopsych.2023.07.010 · Cited by 26
Bedside to bench: the outlook for psychedelic research
Acero, V. P., Cribas, E. S., Browne, K. D., Rivellini, O. M., Burrell, J. C., O’Donnell, J. C., Das, S., & Cullen, D. K. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1240295 · Cited by 28
“In fact, there is evidence that immune mechanisms, such as microglial activation, contribute signi fi cantly to pathologies underlying neurological disorders such as schizophrenia, depression, and Alzheimer ’ s disease (Müller, 2018; Nirzhor et al., 2018; Lee and Giuliani, 2019).”
BackgroundSagarwala, R., & Nasrallah, H. A. (2021) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2021.102688 · Cited by 23
Romero‐Miguel, D., Casquero‐Veiga, M., MacDowell, K. S., Torres-Sánchez, S., Garcia-Partida, J. A., Lamanna‐Rama, N., Romero‐Miranda, A., Berrocoso, E., Leza, J. C., Desco, M., et al. (2021) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyab036 · Cited by 24
“Thus, antioxidant and anti-inflammatory drugs have been proposed as possible therapeutic strategies (Kulak et al., 2013; Muller, 2018).”
BackgroundChoroid plexus volume enlargement in first-episode antipsychotic-naïve schizophrenia
Zeng, J., Zhang, T., Tang, B., Li, S., Li, Y., Bishop, J. R., Sweeney, J. A., Li, Z., Qiu, C., Gu, S., et al. (2024) · Schizophrenia · doi:10.1038/s41537-023-00424-2 · Cited by 24
Neuropsychiatric Drugs Against COVID-19: What is the Clinical Evidence?
Mueller, J. K., Riederer, P. F., & Müller, W. E. (2022) · Pharmacopsychiatry · doi:10.1055/a-1717-2381 · Cited by 22
Schiavone, S., Tucci, P., Trabace, L., & Morgese, M. G. (2019) · Molecules · doi:10.3390/molecules24213993 · Cited by 21
“Accordingly, an imbalance between pro-inflammatory and anti-inflammatory cytokines has been described in both schizophrenia [118] and other psychiatric disorders characterized by psychotic symptoms, such as bipolar disorders [119].”
BackgroundSchizophrenia: Complement Cleaning or Killing
Hogenaar, J. T. T., & van Bokhoven, H. (2021) · Genes · doi:10.3390/genes12020259 · Cited by 22
“Interestingly, it has also been sug‐ gested that inflammation affects dopaminergic neurotransmission [71], which would con‐ nect the dopamine and immunological/neuroimmune hypotheses.”
BackgroundSun, Z., Zhao, L., Bo, Q., Mao, Z., He, Y., Jiang, T., Li, Y., Wang, C., & Li, R. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.711734 · Cited by 23
A Metabolomics Study of Serum in Hospitalized Patients With Chronic Schizophrenia
Okamoto, N., Ikenouchi, A., Watanabe, K., Igata, R., Fujii, R., & Yoshimura, R. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.763547 · Cited by 21
Yu, X., Qi, X., Long, W., Zhao, L., Deng, W., Guo, W., Wang, Q., Ma, X., Hu, X., Ni, P., et al. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15954 · Cited by 19
“When exposed to stimuli such as chronic stress, injury or inflammation, the microglia can be ‘activated’ or ‘sensitized’, by which a lower level of the same stimulus, such as a cytokine response, can cause them to proliferate and increase the production of pro-inflammatory cytokines (Müller, 2018).”
BackgroundEpigenetic Targets in Schizophrenia Development and Therapy
Wawrzczak‐Bargieła, A., Bilecki, W., & Maćkowiak, M. (2023) · Brain Sciences · doi:10.3390/brainsci13030426 · Cited by 29
Human iPSC-Derived Glia as a Tool for Neuropsychiatric Research and Drug Development
Heider, J., Vogel, S., Volkmer, H., & Breitmeyer, R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910254 · Cited by 26
Risk factors for poor COVID-19 outcomes in patients with psychiatric disorders
Cheng, W., Shih, H.-M., Su, K., & Hsueh, P. (2023) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2023.08.024 · Cited by 21
Hatzimanolis, A., Foteli, S., Xenaki, L., Selaković, M., Dimitrakopoulos, S., Vlachos, I. I., Kosteletos, I., Soldatos, R. F., Gazouli, M., Chatzipanagiotou, S., et al. (2024) · Schizophrenia · doi:10.1038/s41537-024-00483-z · Cited by 23
Serum hepcidin / ferroportin levels in bipolar disorder and schizophrenia
Altun, İ. K., Atagün, M. İ., Erdogan, A. R., Yenilmez, D., Yusifova, A., Şenat, A., & Erel, Ö. (2021) · Journal of Trace Elements in Medicine and Biology · doi:10.1016/j.jtemb.2021.126843 · Cited by 22
The Neutrophil‐Lymphocyte Ratio Is Positively Correlated with Aggression in Schizophrenia
Tong, Z., Zhu, J., Wang, J., Yang, Y.-J., & Hu, W. (2022) · BioMed Research International · doi:10.1155/2022/4040974 · Cited by 19
Schizophrenia is associated with altered DNA methylation variance
Kiltschewskij, D. J., Reay, W. R., & Cairns, M. J. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02749-5 · Cited by 24
Wu, H., Liu, Y., Han, Y., Liu, B., Chen, S., Ye, Z., Li, J., Xie, L., & Wu, X. (2024) · Schizophrenia Bulletin Open · doi:10.1093/schizbullopen/sgae026 · Cited by 21
Chen, J., Xue, K., Yang, M., Wang, K., Xu, Y., Wen, B., Cheng, J., Han, S., & Wei, Y. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.821078 · Cited by 21
“The CBF changes in schizophrenia may reflect aberrant neural activity, changes in neurotransmitters, and microvasculature alterations related to neuroinflammation (Kirkpatrick and Miller, 2013; Muller, 2018; Sukumar et al., 2020).”
BackgroundHuang, K., Tang, Y., Chen, Z., Ding, S., Zeng, H., Zhao, Y., Yu, Q., & Liu, Y. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.895178 · Cited by 18
“In recent years, SCZ also has been confirmed to be related to inflammation, which includes circulating cytokines, oxidative stress, and cellular markers (Müller, 2018; Upthegrove and Khandaker, 2019).”
BackgroundZhang, T., Zeng, J., Ye, J., Gao, Y., Hu, Y., Xu, L., Wei, Y., Tang, X., Liu, H., Chen, T., et al. (2023) · Translational Psychiatry · doi:10.1038/s41398-022-02305-1 · Cited by 20
Susai, S. R., Föcking, M., Mongan, D., Heurich, M., Coutts, F., Egerton, A., Whetton, T., Rossum, I. W.-V., Unwin, R. D., Pollak, T. A., et al. (2023) · Schizophrenia Bulletin · doi:10.1093/schbul/sbac201 · Cited by 20
Dang, X., Song, M., Lv, L., Yang, Y., & Luo, X. (2023) · Human Genetics · doi:10.1007/s00439-023-02562-0 · Cited by 21
“2015; Muller 2018).”
Li, Z., Wang, S., Chen, Y., Wu, X. L., Gu, Y., Lang, X., Wu, F., & Zhang, X. (2021) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyab038 · Cited by 21
“Many studies strongly support the hypothesis that the pro-inflammatory pathway is also involved in the pathophysiology of schizophrenia (Müller, 2018; Zhu et al., 2020).”
Calovi, S., Mut-Arbona, P., Tod, P., Iring, A., Nicke, A., Mato, S., Vizi, E. S., Tønnesen, J., & Sperlágh, B. (2020) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.566251 · Cited by 22
“Additionally, dysfunctional P2rx7 expression hints to a deregulated prefrontal dopaminergic tone, which leads to a complex scenario: it is predicted that basal dopamine release and the related compensatory mechanisms in the PFC have an inverted ‘‘U’’ relationship with PFC performance and was shown to be relevant to SC…”
BackgroundInfluentialJeong, S. H., & Kim, Y. S. (2021) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2021.19.3.411 · Cited by 16
“Schizophrenia and Altered Immune Function The hypothesis that schizophrenia is deeply linked to immune dysfunction has been raised for decades [21].”
BackgroundPapavă, I., Dehelean, L., Romoșan, R. S., Bondrescu, M., Dimeny, C. Z., Domuța, E. M., Bratosin, F., Bogdan, I. G., Grigoraş, M. L., Țigmeanu, C. V., et al. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19116501 · Cited by 17
“Other studies have shown the presence of pro-inflammatory markers in the blood and cerebrospinal fluid of patients with schizophrenia [21,43].”
BackgroundThe Interrelation between Interleukin-2 and Schizophrenia
Huang, Y., Zhang, X., & Zhou, N. (2022) · Brain Sciences · doi:10.3390/brainsci12091154 · Cited by 17
“At present, dopamine hypothesis [7] and neuroinflammation theory [8] are widely recognized.”
BackgroundMethodThe Role of Total White Blood Cell Count in Antipsychotic Treatment for Patients with Schizophrenia
Zhang, Y., Tao, S., Coid, J. W., Wei, W., Wang, Q., Yue, W., Yan, H., Tan, L., Chen, Q., Yang, G., et al. (2023) · Current Neuropharmacology · doi:10.2174/1570159x21666230104090046 · Cited by 19
“Although the underlying etiology remains unclear, several hypotheses have been proposed, including low-grade inflammation [2].”
Bejerot, S., Eklund, D., Hesser, H., Hietala, M. A., Kariis, T., Lange, N., Lebedev, A. V., Montgomery, S., Nordenskjöld, A., Petrović, P., et al. (2023) · BMC Psychiatry · doi:10.1186/s12888-023-05250-5 · Cited by 18
Leung, P. B. M., Liu, Z., Zhong, Y., Tubbs, J. D., Forti, M. D., Murray, R. M., So, H., Sham, P. C., & Lui, S. S. Y. (2024) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2024.02.015 · Cited by 17
Mamun-or-Rashid, Roknuzzaman, A. S. M., Sarker, R., Nayem, J., Bhuiyan, M. A., Islam, M. R., & Mahmud, Z. A. (2024) · Scientific Reports · doi:10.1038/s41598-024-66131-9 · Cited by 25
Chen, D., Li, H., Zhao, Q., Song, J., Chen, L., & Yu, J. (2021) · Psychiatry Research · doi:10.1016/j.psychres.2021.113717 · Cited by 20
Concordance of Immune-Related Markers in Lymphocytes and Prefrontal Cortex in Schizophrenia
Gatta, E., Saudagar, V., Drnevich, J. M., Forrest, M. P., Auta, J., Clark, L. V., Sershen, H. W., Smith, R. C., Grayson, D. R., Davis, J. M., et al. (2021) · Schizophrenia Bulletin Open · doi:10.1093/schizbullopen/sgab002 · Cited by 18
Filho, A. J. M. C., Mottin, M., Soares, M. V.-R., Jucá, P. M., Andrade, C. H., & Macêdo, D. S. (2021) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000585 · Cited by 19
“Also, an increased inflammatory response is proposed to be present in a group of schizophrenia patients, as an inflammatory phenotype subgroup, and possibly not for all patients (Müller, 2018).”
BackgroundLncRNA RP5-998N21.4 promotes immune defense through upregulation of IFIT2 and IFIT3 in schizophrenia
Guo, B., Jiang, T., Wu, F., Ni, H., Ye, J., Wu, X., Ni, C., Jiang, M., Ye, L., Li, Z., et al. (2022) · Schizophrenia · doi:10.1038/s41537-021-00195-8 · Cited by 21
“Several studies indicate that prenatal viral/bacterial infections, inflammation, and immune activation increase the offspring’s risk for developing schizophrenia.(26) Recently, lncRNAs have emerged as potential key regulators of inflammatory responses(7).”
BackgroundLi, Y., Li, Y., Fang, X., Chen, D., Yu, W., & Zhu, Z. (2024) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2024.1365448 · Cited by 20
“Recent research has also found that patients with schizophrenia often exhibit high levels of peripheral inflammatory markers, such as C-reactive protein (CRP) and pro-inflammatory factors (Müller, 2018; Murphy et al., 2022).”
BackgroundWu, H., Jiawei, X., Wen, Z., Han, Y., Liu, Y., Chen, S., Ye, Z., Li, J., Xie, L., & Wu, X. (2025) · Schizophrenia Bulletin · doi:10.1093/schbul/sbaf028 · Cited by 17
Mild Behavioral Impairment: An Early Sign and Predictor of Alzheimer's Disease Dementia
Jiang, F., Cheng, C., Huang, J., Chen, Q., & Le, W. (2022) · Current Alzheimer Research · doi:10.2174/1567205019666220805114528 · Cited by 22
MiRNA Differences Related to Treatment-Resistant Schizophrenia
Pérez-Rodríguez, D., Penedo, M. A., Baltanás, T. R., Centeno, T. P., Burkhardt, S., Fischer, A., Prieto-González, J. M., Olivares, J. M., López-Fernández, H., & Agís‐Balboa, R. C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24031891 · Cited by 18
Exosome and exosomal contents in schizophrenia
Zhang, T., Fang, Y., Wang, L., Gu, L., & Tang, J. (2023) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2023.05.072 · Cited by 20
Modeling psychotic disorders: Environment x environment interaction
Murlanova, K., & Pletnikov, M. V. (2023) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2023.105310 · Cited by 17
Prospects and Pitfalls of Plasma Complement C4 in Schizophrenia: Building a Better Biomarker
Severance, E. G., Prandovszky, E., Yang, S., Leister, F. J., Lea, A., Wu, C., Tamouza, R., Leboyer, M., Dickerson, F., & Yolken, R. H. (2023) · Developmental Neuroscience · doi:10.1159/000534185 · Cited by 18
Zhu, X., Wang, C., Yu, J.-F., Weng, J., Han, B., Liu, Y., Tang, X., & Pan, B. (2023) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2023.1256184 · Cited by 20
“In addition, levels of pro-inflammatory biomarkers, such as cytokines, were shown to be elevated in the cerebrospinal fluid and peripheral blood of schizophrenia patients (Muller, 2018).”
BackgroundInflammation and olfactory loss are associated with at least 139 medical conditions
Leon, M., Troscianko, E. T., & Woo, C. C. (2024) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2024.1455418 · Cited by 20
Igg‐Dependent Hydrolysis of Myelin Basic Protein of Patients with Different Courses of Schizophrenia
Parshukova, D. A., Smirnova, L. P., Kornetova, E. G., Semke, A. V., Buneva, V. N., & Ivanova, S. А. (2020) · Journal of Immunology Research · doi:10.1155/2020/8986521 · Cited by 16
Zhang, J., Yang, L., Fang, Z., Kong, J., Huang, Q., & Xu, H. (2018) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-018-9799-0 · Cited by 16
“And a low-level neuroinflammatory process is accompanied with microglial activation demonstrated in neuroimaging studies (Müller 2018; Müller et al. 2015).”
BackgroundDisease severity across psychiatric disorders is linked to pro-inflammatory cytokines
Solomon, P., Budde, M., Kohshour, M. O., Adorjan, K., Heilbronner, M., Navarro‐Flores, A., Papiol, S., Reich‐Erkelenz, D., Schulte, E. C., Senner, F., et al. (2025) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2025.06.004 · Cited by 21
Ouyang, H., Huang, M., Xu, Y., Yao, Q., Wu, X., & Zhou, D. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.652314 · Cited by 15
The effects of mango leaf extract during adolescence and adulthood in a rat model of schizophrenia
Garcia-Partida, J. A., Torres-Sánchez, S., MacDowell, K. S., Fernández-Ponce, M. T., Casas, L., Mantell, C., Soto‐Montenegro, M. L., Romero‐Miguel, D., Lamanna‐Rama, N., Leza, J. C., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.886514 · Cited by 20
“…(e.g., increased brain-blood barrier permeability and glial activation), and changes to inflammatory pathways (cytokine imbalances) and in oxidative stress (redox dysregulation) are key aspects of the pathophysiology of SZ (rev. in Leza et al., 2015; Müller, 2018; Upthegrove and Khandaker, 2020).”
BackgroundFerranti, A. S., & Foster, D. J. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.925792 · Cited by 15
“This includes changes in numerous cytokine levels in the blood and cerebrospinal fluid of schizophrenia patients, as well as in the increased comorbidity of schizophrenia with auto-immune disorders (Muller, 2018).”
BackgroundThe emerging role of long non-coding RNAs in schizophrenia
Wu, G., Du, X., Li, Z., Du, Y., Lv, J., Li, X., Xu, Y., & Liu, S. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.995956 · Cited by 21
Zhong, H., Huan, X., Jiao, K., Shen, H., Wen, Z., Zhao, R., Goh, L.-Y., Su, M., Song, J., Yan, C., et al. (2022) · Autoimmunity Reviews · doi:10.1016/j.autrev.2022.103214 · Cited by 19
Krzyściak, W., Karcz, P., Bystrowska, B., Szwajca, M., Bryll, A., Śmierciak, N., Ligezka, A. N., Turek, A., Kozicz, T., Skalniak, A., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11020240 · Cited by 15
Ketogenic Diet and Inflammation: Implications for Mood and Anxiety Disorders
Karkafi, R. E., Gebara, T., Salem, M., Kamel, J., Khoury, G. E., Zalal, M., & Fakhoury, M. (2023) · Advances in experimental medicine and biology · doi:10.1007/978-981-19-7376-5_23 · Cited by 22
Mut-Arbona, P., & Sperlágh, B. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2023.109541 · Cited by 18
“Transient expression of the receptor during brain development affects dendrite branching and spine density (Mut-Arbona et al., 2023).”
BackgroundWeiser, M., Levi, L. W., Park, J., Nastas, I., Matei, V. P., Davidson, M. H., Arad, I., Dudkiewicz, I., & Davis, J. M. (2023) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2023.04.007 · Cited by 14
Wang, D., Chen, D., Xiu, M., Wang, L., Kosten, T. R., & Zhang, X. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01760-8 · Cited by 16
Metadata
- Authors
- Müller, N.
- Affiliations
- Ludwig-Maximilians-Universität München (DE)
- Corresponding author
- Müller, Norbert
- ORCID
- Müller, Norbert
- Venue
- Schizophrenia Bulletin
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-04-10
- Volume
- 44
- Issue
- 5
- Pages
- 973-982
- ISSN
- 0586-7614 (ISSN-L)
- 1745-1701
- PMC
- PMC6101562
- OpenAlex
- W2888647009
- Cited by
- 648
- References
- 130
- Citations by year
- 2026: 62 · 2025: 88 · 2024: 92 · 2023: 116 · 2022: 102 · 2021: 98 · 2020: 62 · 2019: 18 · 2018: 9
- FWCI
- 4.08
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- Schizophrenia Bulletin (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- schizophrenia, neuroinflammation
- MeSH terms
- Animals, Anti-Inflammatory Agents, Humans, Inflammation, Schizophrenia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.